AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03690245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initiation of Resuscitation While Attached to the Cord
Description: Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
Study NCT01829451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------
Study NCT03397953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
Study NCT03367689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study NCT04094740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Injector without A Needle
Description: Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
Study NCT00480324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two-dose oral vaccination.
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.
Study NCT00480324 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration.
Study NCT04382430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided venous access
Description: Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
Study NCT04382430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
Study NCT03956589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi
Description: Open label of Orkambi treatment during 3 months
Study NCT01191476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalational Induction and Maintenance
Description: Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
Study NCT01191476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Target Controlled Infusion for Induction and Maintenance
Description: Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
Study NCT01191476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance
Description: Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
Study NCT03297294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401
Description: capsules, oral
Study NCT03297294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to EMA401 capsules, oral
Study NCT03297294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to EMA401 capsules, oral
Study NCT02127073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
Study NCT02244424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tools for Teen Moms
Description: The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life.
Study NCT02754284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fat transplantation
Description: Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
Study NCT02754284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold transplantation
Description: Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
Study NCT02488824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Temperature
Description: Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
Study NCT02488824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Temperature
Description: Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
Study NCT00689845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00689845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study NCT01291004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel/ethinyl estradiol and ethinyl estradiol
Description: Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given subcutaneously
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT03015922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide or Pomalidomide
Description: Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
Study NCT03015922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REOLYSIN
Description: Patients will receive Reolysin alongside either lenalidomide or pomalidomide
Study NCT02401750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Naltrexone (a)
Study NCT02401750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Naltrexone (b)
Study NCT02401750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matches both experimental drugs
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules.
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets.
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion.
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab IV infusion.
Study NCT02327169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan IV infusion.
Study NCT01334255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iSONEP (sonepcizumab/LT1009)
Description: Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
Study NCT00737789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine slow-release granules
Description: Mesalazine 2g Sachet prolonged release granules, administered orally.
Study NCT00737789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine slow-release granules
Description: Mesalazine 2g Sachet prolonged release granules, administered orally.
Study NCT00737789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine liquid enema
Description: 1g mesalazine liquid enema, administered topically once a day in the evening.
Study NCT00737789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine liquid enema
Description: 1g mesalazine liquid enema, administered topically once a day in the evening.
Study NCT01291004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day drospirenone oral contraceptive
Description: Drospirenone/ethinyl estradiol 0.3/0.02 mg
Study NCT02946203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barium Sulfate
Description: Barium Sulfate Oral Contrast-VoLumen
Study NCT02946203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored beverage Oral Contrast
Description: Flavored beverage for neutral abdominal/pelvic imaging
Study NCT01349478 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOKOMAT
Description: Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
Study NCT00427037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 50,000 IU weekly by mouth
Study NCT00427037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo pill orally by mouth
Study NCT04871620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: >15% SV increase during fluid challenge
Description: The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
Study NCT00809822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPB-01
Description: Intravenous immunoglobulin
Study NCT00809822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study NCT02055508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study NCT02055508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-Management-Phone-Calls
Study NCT02055508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care-Management-Phone-Calls
Study NCT04049669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be taken by mouth twice daily during radiation and throughout each chemo-immunotherapy treatment cycle.
Study NCT04049669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Radiation
Description: Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
Study NCT04049669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Full-dose Radiation
Description: Palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine).
Study NCT04049669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be taken by mouth once daily, on days 1-5 of each chemo-immunotherapy treatment cycle.
Study NCT04049669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Study NCT04049669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Study NCT04049669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Lomustine will be taken by mouth once daily, on day 1 of each chemo-immunotherapy treatment cycle.
Study NCT01744782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103
Description: Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Tablet, Oral, 5 mg, Once daily in the morning
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5 mg
Description: Tablet, Oral, 5 mg, Once daily in the morning
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 5 mg for Saxagliptin
Description: Tablet, Oral, 5 mg, Once daily in the morning
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 500 mg for metformin (with titration)
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg with titration
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study NCT02273050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg with titration
Description: Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Given orally
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00689845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: Given IV
Study NCT04003818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEICOPLANIN
Description: Pharmaceutical form:solution for oral administration Route of administration: oral
Study NCT02785653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
Study NCT02785653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
Study NCT02785653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
Study NCT02409329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
Study NCT02409329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helpline and A1c results
Description: Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
Study NCT01126801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Oral estradiol 1.0 mg/day for four weeks.
Study NCT02409329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpline and A1c results
Description: Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
Study NCT02409329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH + FAMS
Description: The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
Study NCT01588535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
Study NCT03513614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored axillary surgery - both Arms
Description: Axillary lymph node dissection - Arm A
Study NCT01588535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution, five drops in affected ear canal each hour as needed
Study NCT03513614 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Arm A
Description: Regional nodal irradiation excluding the dissected axilla - Arm A
Study NCT03513614 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Arm B
Description: Regional nodal irradiation including the full axilla - Arm B
Study NCT04678258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HR electroanatomic mapping and MVG catheter ablation
Description: High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
Study NCT04678258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bipolar mapping and linear catheter ablation
Description: Bipolar mapping and conventional anatomic linear catheter ablation
Study NCT01126801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control matched to estradiol tablets. Daily dosing for one month.
Study NCT03076320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDF+M-DDO
Description: Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
Study NCT03076320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A+PBO
Description: Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
Study NCT01117467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation scenario
Description: Students performing their scenario will be paired, not solo
Study NCT01117467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation scenario
Description: Students will perform their simulation scenario solo and receive feedback within the group
Study NCT02808819 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 4 weeks
Study NCT02808819 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously every 8 weeks
Study NCT03041207 — intervention group
Intervention type: BEHAVIORAL
Intervention: Development and implementation of an antibiotic guideline
Description: A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
Study NCT01118117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Misago™ Self-Expanding Stent System
Description: Transcatheter placement of an intravascular stent(s)
Study NCT03588650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX20
Description: a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
Study NCT02118168 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is foreseen in this Observational Study